Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205231 · ClinicalTrials.gov registry record · NA
A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease
A NA study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT00205231 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 25 participants.
The verdict
NCT00205231, a NA study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This pilot study will investigate the safety and effect of etanercept in HIV infection by studying HIV replication and immune function (as measured by CD4 counts) in individuals with HIV infection.
Interventions
- DRUG etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-05 |
| Est. Completion | 2004-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00205231
The ClinicalTrials.gov registry entry for NCT00205231 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which etanercept is the first listed.
NCT00205231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00205231 about?
NCT00205231 is a clinical study titled "A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease". This pilot study will investigate the safety and effect of etanercept in HIV infection by studying HIV replication and immune function (as measured by CD4 counts) in individuals with HIV infection.
What is the current status of trial NCT00205231?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2002-05. Estimated completion is 2004-05-01.
What interventions are being tested in trial NCT00205231?
The interventions under investigation include: etanercept (DRUG).
Who is sponsoring clinical trial NCT00205231?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.